Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Metabolic, Cardiovascular, and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Jakarta Provincial Health Department, Indonesia.
Prim Care Diabetes. 2022 Feb;16(1):65-68. doi: 10.1016/j.pcd.2021.11.002. Epub 2021 Nov 12.
While the higher prevalence of diabetes mellitus (DM) at younger age in Indonesia might contribute to the relatively higher COVID-19 mortality rate in Indonesia, there were currently no available evidence nor specific policy in terms of COVID-19 prevention and management among DM patients. We aimed to find out the association between diagnosed diabetes mellitus (DM) with COVID-19 mortality in Indonesia.
We performed a retrospective cohort study using Jakarta Province's COVID-19 epidemiological registry within the first 6 months of the pandemic. All COVID-19 confirmed patients, aged >15 years with known DM status were included. Patients were assessed for their clinical symptoms and mortality outcome based on their DM status. A multivariate Cox-regression test was performed to obtain the relative risk (RR) of COVID-19 mortality in the diagnosed DM group.
Of 20,481 patients with COVID-19, 705 (3.4%) had DM. COVID-19 mortality rate in DM group was 21.28%, significantly higher compared to 2.77% mortality in the non-DM group [adjusted RR 1.98 (CI 95% 1.57-2.51), p < 0.001]. In addition, COVID-19 patients with DM generally developed more symptoms.
DM is associated not only with development of more COVID-19 clinical symptoms, but also with a higher risk of COVID-19 mortality. This finding may provide a basis for future policy regarding COVID-19 prevention and management among diabetes patients in Indonesia.
印度尼西亚年轻人中糖尿病(DM)的患病率较高,这可能导致印度尼西亚 COVID-19 死亡率相对较高,但目前尚无针对 DM 患者 COVID-19 预防和管理的相关证据或具体政策。我们旨在探讨在印度尼西亚,确诊的糖尿病(DM)与 COVID-19 死亡率之间的关系。
我们使用大流行前 6 个月雅加达省 COVID-19 流行病学登记处进行了一项回顾性队列研究。所有年龄> 15 岁且已知 DM 状态的 COVID-19 确诊患者均被纳入研究。根据 DM 状态评估患者的临床症状和死亡结局。采用多变量 Cox 回归检验来评估确诊 DM 组 COVID-19 死亡率的相对风险(RR)。
在 20481 例 COVID-19 患者中,有 705 例(3.4%)患有 DM。DM 组 COVID-19 死亡率为 21.28%,明显高于非 DM 组的 2.77%死亡率[校正 RR 1.98(95%CI 1.57-2.51),p<0.001]。此外,患有 DM 的 COVID-19 患者通常表现出更多的症状。
DM 不仅与 COVID-19 临床症状的发展有关,而且与 COVID-19 死亡率的增加有关。这一发现可能为印度尼西亚未来针对糖尿病患者 COVID-19 预防和管理的政策提供依据。